Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025)

Ovid Therapeutics' Current Deferred Revenue history spans 2 years, with the latest figure at $718000.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed N/A year-over-year to $718000.0; the TTM value through Sep 2025 reached $718000.0, changed N/A, while the annual FY2020 figure was $2.2 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $718000.0 in Q3 2025 per OVID's latest filing, roughly flat from $718000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $718000.0 in Q2 2025 to a low of $718000.0 in Q2 2025.